These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33325393)

  • 1. Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.
    Desaphy JF; Altamura C; Vicart S; Fontaine B
    J Neuromuscul Dis; 2021; 8(3):357-381. PubMed ID: 33325393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug repurposing in skeletal muscle ion channelopathies.
    Altamura C; Saltarella I; Campanale C; Laghetti P; Desaphy JF
    Curr Opin Pharmacol; 2023 Feb; 68():102329. PubMed ID: 36512979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation spectrum and health status in skeletal muscle channelopathies in Japan.
    Sasaki R; Nakaza M; Furuta M; Fujino H; Kubota T; Takahashi MP
    Neuromuscul Disord; 2020 Jul; 30(7):546-553. PubMed ID: 32660787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands.
    Stunnenberg BC; Raaphorst J; Deenen JCW; Links TP; Wilde AA; Verbove DJ; Kamsteeg EJ; van den Wijngaard A; Faber CG; van der Wilt GJ; van Engelen BGM; Drost G; Ginjaar HB
    Neuromuscul Disord; 2018 May; 28(5):402-407. PubMed ID: 29606556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Channelopathies.
    Moxley III
    Curr Treat Options Neurol; 2000 Jan; 2(1):31-47. PubMed ID: 11096735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence study of genetically defined skeletal muscle channelopathies in England.
    Horga A; Raja Rayan DL; Matthews E; Sud R; Fialho D; Durran SC; Burge JA; Portaro S; Davis MB; Haworth A; Hanna MG
    Neurology; 2013 Apr; 80(16):1472-5. PubMed ID: 23516313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights into the pathomechanisms of skeletal muscle channelopathies.
    Burge JA; Hanna MG
    Curr Neurol Neurosci Rep; 2012 Feb; 12(1):62-9. PubMed ID: 22083238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses.
    Statland JM; Barohn RJ
    Continuum (Minneap Minn); 2013 Dec; 19(6 Muscle Disease):1598-614. PubMed ID: 24305449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of Nondystrophic Skeletal Muscle Channelopathies in Children.
    Al-Ghamdi F; Darras BT; Ghosh PS
    Pediatr Neurol; 2017 May; 70():26-33. PubMed ID: 28325641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State of the art in hereditary muscle channelopathies.
    Jurkat-Rott K; Lehmann-Horn F
    Acta Myol; 2010 Oct; 29(2):343-50. PubMed ID: 21314017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Challenges Resulting From the Loss of Function of Na
    Nicole S; Lory P
    Front Pharmacol; 2021; 12():751095. PubMed ID: 34671263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines on clinical presentation and management of nondystrophic myotonias.
    Stunnenberg BC; LoRusso S; Arnold WD; Barohn RJ; Cannon SC; Fontaine B; Griggs RC; Hanna MG; Matthews E; Meola G; Sansone VA; Trivedi JR; van Engelen BGM; Vicart S; Statland JM
    Muscle Nerve; 2020 Oct; 62(4):430-444. PubMed ID: 32270509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle channelopathies.
    Vivekanandam V; Jayaseelan D; Hanna MG
    Handb Clin Neurol; 2023; 195():521-532. PubMed ID: 37562884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium channelopathies of skeletal muscle result from gain or loss of function.
    Jurkat-Rott K; Holzherr B; Fauler M; Lehmann-Horn F
    Pflugers Arch; 2010 Jul; 460(2):239-48. PubMed ID: 20237798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle channelopathies.
    Statland J; Phillips L; Trivedi JR
    Neurol Clin; 2014 Aug; 32(3):801-15, x. PubMed ID: 25037091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy in myotonic disorders and in muscle channelopathies.
    Meola G; Sansone V
    Neurol Sci; 2000; 21(5 Suppl):S953-61. PubMed ID: 11382195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing.
    Vivekanandam V; Jaibaji R; Sud R; Ellmers R; Skorupinska I; Germaine L; James N; Holmes S; Mannikko R; Jayaseelan D; Hanna MG
    Neuromuscul Disord; 2023 Mar; 33(3):270-273. PubMed ID: 36796140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.
    Platt D; Griggs R
    Curr Opin Neurol; 2009 Oct; 22(5):524-31. PubMed ID: 19571750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for periodic paralysis.
    Sansone V; Meola G; Links TP; Panzeri M; Rose MR
    Cochrane Database Syst Rev; 2008 Jan; (1):CD005045. PubMed ID: 18254068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostics in skeletal muscle channelopathies.
    Vicino A; Brugnoni R; Maggi L
    Expert Rev Mol Diagn; 2023; 23(12):1175-1193. PubMed ID: 38009256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.